Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases

Published:September 27, 2012DOI:



      This phase II randomized, placebo-controlled study was conducted to evaluate efficacy and safety of radium-223 in patients with castration-resistant prostate cancer (CRPC) and painful bone metastases. Twelve- and 18-month survival results were reported previously. Here we report 24-month overall survival (OS) and safety data from the period 12 to 24 months after the first injection of study medication.


      Patients with CRPC and bone pain were randomized 1:1 to receive 4 injections of radium-223 (50 kBq/kg [n = 33]) or placebo (n = 31) after external-beam radiotherapy; each injection was given every 4 weeks. Endpoints for this report were 24-month OS, long-term safety, and treatment-related adverse events (AEs) occurring in the 12- to 24-month period.


      After 24 months, 10 (30%) patients were alive in the radium-223 group compared with 4 patients (13%) in the placebo group. Patients who received at least 1 dose of study medication had a median OS of 65 weeks in the radium-223 group vs. 46 weeks in the placebo group (log-rank P = .056). The hazard ratio (HR) for OS, adjusted for baseline covariates, was 0.476 (95% confidence interval [CI], 0.258-0.877; Cox regression P = .017). The most frequent cause of death for both arms was disease progression. There were no reports of treatment-related AEs or long-term hematologic toxicity during the 12- to 24-month follow-up.


      Radium-223 had a highly favorable safety profile, with no evidence of second malignancies at 24-month follow-up. The significant improvement in OS observed in patients receiving radium-223 vs. placebo suggests that treatment of bone disease with radium-223 has survival benefits.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mundy G.R.
        Metastasis to bone: causes, consequences, and therapeutic opportunities.
        Nat Rev Cancer. 2002; 2: 584-593
        • Lange P.H.
        • Vessella R.L.
        Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone.
        Cancer Metastasis Rev. 1999; 17: 331-336
        • Goltzman D.
        Mechanisms of the development of osteoblastic metastases.
        Cancer. 1997; 80: 1581-1587
        • Boyce B.F.
        • Yoneda T.
        • Guise T.A.
        Factors regulating the growth of metastatic cancer in bone.
        Endocr Relat Cancer. 1999; 6: 333-347
        • Lipton A.
        Implications of bone metastases and the benefits of bone-targeted therapy.
        Semin Oncol. 2010; 37: S15-S29
        • Scher H.I.
        • Fizazi K.
        • Saad F.
        • et al.
        Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study.
        J Clin Oncol. 2012; 30 (abstract LBA1)
        • Petrylak D.P.
        • Tangen C.M.
        • Hussain M.H.
        • et al.
        Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
        N Engl J Med. 2004; 351: 1513-1520
        • Tannock I.F.
        • de Wit R.
        • Berry W.R.
        • et al.
        Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
        N Engl J Med. 2004; 351: 1502-1512
        • de Bono J.S.
        • Oudard S.
        • Ozguroglu M.
        • et al.
        Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
        Lancet. 2010; 376: 1147-1154
        • Danila D.C.
        • Morris M.J.
        • de Bono J.S.
        • et al.
        Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
        J Clin Oncol. 2010; 28: 1496-1501
        • Attard G.
        • Reid A.H.
        • A'Hern R.
        • et al.
        Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
        J Clin Oncol. 2009; 27: 3742-3748
        • Adami S.
        Bisphosphonates in prostate carcinoma.
        Cancer. 1997; 80: 1674-1679
        • Smith M.R.
        • Saad F.
        • Egerdie B.
        • et al.
        Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
        J Urol. 2009; 182: 2670-2675
        • Smith M.R.
        • Egerdie B.
        • Hernandez T.N.
        • et al.
        Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
        N Engl J Med. 2009; 361: 745-755
        • Silberstein E.B.
        Systemic radiopharmaceutical therapy of painful osteoblastic metastases.
        Semin Radiat Oncol. 2000; 10: 240-249
        • Henriksen G.
        • Breistøl K.
        • Bruland O.S.
        • et al.
        Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model.
        Cancer Res. 2002; 62: 3120-3125
        • Bruland O.S.
        • Nilsson S.
        • Fisher D.R.
        • et al.
        High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?.
        Clin Cancer Res. 2006; 12: 6250s-6257s
        • Lewington V.J.
        Bone-seeking radionuclides for therapy.
        J Nucl Med. 2005; 46: 38S-47S
        • Liepe K.
        Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer.
        Curr Opin Investig Drugs. 2009; 10: 1346-1358
        • McDevitt M.R.
        • Sgouros G.
        • Finn R.D.
        • et al.
        Radioimmunotherapy with alpha-emitting nuclides.
        Eur J Nucl Med. 1998; 25: 1341-1351
        • Kerr C.
        (223)Ra targets skeletal metastases and spares normal tissue.
        Lancet Oncol. 2002; 3: 453
        • Li Y.
        • Russell P.J.
        • Allen B.J.
        Targeted alpha-therapy for control of micrometastatic prostate cancer.
        Expert Rev Anticancer Ther. 2004; 4: 459-468
        • Henriksen G.
        • Fisher D.R.
        • Roeske J.C.
        • et al.
        Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice.
        J Nucl Med. 2003; 44: 252-259
        • Nilsson S.
        • Larsen R.H.
        • Fosså S.D.
        • et al.
        First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.
        Clin Cancer Res. 2005; 11: 4451-4459
        • Nilsson S.
        • Franzén L.
        • Parker C.
        • et al.
        Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
        Lancet Oncol. 2007; 8: 587-594
        • Nilsson S.
        • Strang P.
        • Aksnes A.K.
        • et al.
        A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.
        Eur J Cancer. 2012; 48: 678-686
        • Parker C.
        • Heinrich D.
        • O'Sullivan J.M.
        Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA).
        Ann Oncol. 2011; 22 (abstract 1LBA): v10-v18
        • Halabi S.
        • Small E.J.
        • Kantoff P.W.
        • et al.
        Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.
        J Clin Oncol. 2003; 21 (Errata): 1232-1237J Clin Oncol. 2004; 22 (Errata): 3434